Atazanavir/ritonavir + lamivudine/zidovudine - Mylan pharmaceuticals

Drug Profile

Atazanavir/ritonavir + lamivudine/zidovudine - Mylan pharmaceuticals

Alternative Names: Ritonavir/atazanavir + zidovudine/lamivudine - Mylan pharmaceuticals

Latest Information Update: 04 Aug 2015

Price : $50

At a glance

  • Originator Mylan Pharmaceuticals
  • Class Amides; Azides; Carbamates; Dideoxynucleosides; Oligopeptides; Pyridines; Pyrimidine nucleosides; Small molecules; Thiazoles
  • Mechanism of Action HIV protease inhibitors; Nucleoside reverse transcriptase inhibitors; RNA-directed DNA polymerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preregistration HIV-1 infections

Most Recent Events

No Data Available
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top